Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scott Obach

Showing results (71-80 of 193) with videos related to

Pageof 20
Sort By:
Biopharmaceutics & Drug Disposition|January 4, 2012
Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse eventsChristopher L Shaffer, Renato J Scialis, Haojing Rong, et al.
Chemical Research in Toxicology|August 12, 2008
Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily doseR Scott Obach, Amit S Kalgutkar, John R Soglia, et al.
Chemical Research in Toxicology|August 19, 2008
In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicamR Scott Obach, Amit S Kalgutkar, Tim F Ryder, et al.
Journal of Medicinal Chemistry|April 30, 2014
Clearance mechanism assignment and total clearance prediction in human based upon in silico modelsFranco Lombardo, R Scott Obach, Manthena V Varma, et al.
Current Drug Metabolism|October 8, 2003
Drug metabolism and drug interactions: application and clinical value of in vitro modelsKarthik Venkatakrishnan, Lisa L von Moltke, R Scott Obach, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 23, 2003
Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofenJohn P O'Donnell, Deepak K Dalvie, Amit S Kalgutkar, et al.
Chemico-Biological Interactions|October 22, 2008
Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicityDennis A Smith, R Scott Obach, Dominic P Williams, et al.
Drug Metabolism Reviews|March 17, 2007
What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugsSarah J Roffey, R Scott Obach, Jenny I Gedge, et al.
Chemical Research in Toxicology|January 28, 2009
A strategy for the risk assessment of human genotoxic metabolitesKrista L Dobo, R Scott Obach, Debra Luffer-Atlas, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 3, 2021
Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate ConstantsHeather Eng, Elaine Tseng, Matthew A Cerny, et al.
Pageof 20

Showing results (71-80 of 193) with videos related to

Sort By:
Pageof 20
Biopharmaceutics & Drug Disposition|January 4, 2012
Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse eventsChristopher L Shaffer, Renato J Scialis, Haojing Rong, et al.
Chemical Research in Toxicology|August 12, 2008
Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily doseR Scott Obach, Amit S Kalgutkar, John R Soglia, et al.
Chemical Research in Toxicology|August 19, 2008
In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicamR Scott Obach, Amit S Kalgutkar, Tim F Ryder, et al.
Journal of Medicinal Chemistry|April 30, 2014
Clearance mechanism assignment and total clearance prediction in human based upon in silico modelsFranco Lombardo, R Scott Obach, Manthena V Varma, et al.
Current Drug Metabolism|October 8, 2003
Drug metabolism and drug interactions: application and clinical value of in vitro modelsKarthik Venkatakrishnan, Lisa L von Moltke, R Scott Obach, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 23, 2003
Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofenJohn P O'Donnell, Deepak K Dalvie, Amit S Kalgutkar, et al.
Chemico-Biological Interactions|October 22, 2008
Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicityDennis A Smith, R Scott Obach, Dominic P Williams, et al.
Drug Metabolism Reviews|March 17, 2007
What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugsSarah J Roffey, R Scott Obach, Jenny I Gedge, et al.
Chemical Research in Toxicology|January 28, 2009
A strategy for the risk assessment of human genotoxic metabolitesKrista L Dobo, R Scott Obach, Debra Luffer-Atlas, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 3, 2021
Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate ConstantsHeather Eng, Elaine Tseng, Matthew A Cerny, et al.
Pageof 20